Literature DB >> 30417637

Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal.

G Carli1, A Farsi1, F Chiarini1, D Lippolis2, G Cortellini2.   

Abstract

Summary: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly being used in hospital and outpatient settings as safe alternatives to warfarin. Hypersensitivity reactions have been described for NOACs and can be classified according to Gell and Coombs. We reviewed case reports of possible drug hypersensitivity reactions, noticing a predominance of delayed reactions (both mild and severe) and the absence of cross-reactions to warfarin and low molecu-lar weight heparins. International experience on diagnostic tests is lacking. The vast majority of authors refer to probability scores and rely on biopsy to classify vasculitis and rule out differential diagnoses. We propose to adapt available tests to confirm the patient's reactivity to new anticoagulants. Among in vivo tests, patch testing revealed promising in delayed reactions.

Entities:  

Keywords:  apixaban; dabigatran; edoxaban; hypersensitivity; novel oral anticoagulants or non-vitamin K oral anticoagulants (NOACs); rivaroxaban

Year:  2018        PMID: 30417637     DOI: 10.23822/EurAnnACI.1764-1489.80

Source DB:  PubMed          Journal:  Eur Ann Allergy Clin Immunol        ISSN: 1764-1489


  4 in total

Review 1.  Role of direct oral anticoagulants in patients with kidney disease.

Authors:  Vimal K Derebail; Michelle N Rheault; Bryce A Kerlin
Journal:  Kidney Int       Date:  2019-12-24       Impact factor: 10.612

2.  A rare case report of apixaban-induced lichenoid eruption.

Authors:  Tanvi Patil; Suzanne Hanna; Wayne Torre
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

Review 3.  Perioperative Antithrombotic Management During Gastroenterological Surgery in Patients With Thromboembolic Risks: Current Status and Future Prospects.

Authors:  Takahisa Fujikawa
Journal:  Cureus       Date:  2022-03-24

4.  Complementary Use of U.S. FDA's Adverse Event Reporting System and Sentinel System to Characterize Direct Oral Anticoagulants-Associated Cutaneous Small Vessel Vasculitis.

Authors:  Mohamed Mohamoud; Casie Horgan; Efe Eworuke; Elizabeth Dee; Justin Bohn; Oren Shapira; Monica A Munoz; Danijela Stojanovic; Veronica Sansing-Foster; Adebola Ajao; Lois La Grenade
Journal:  Pharmacotherapy       Date:  2020-11-08       Impact factor: 6.251

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.